Eli Lilly | LLY - Trade Debtors


Eli Lilly reported $23.48B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Abbott USD 11.22B 655M Mar/2026
ALKERMES USD 456.48M 48.85M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
Baxter International USD 1.86B 158M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Drreddys Laboratories INR 123.17B 121.76B Mar/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
J&J USD 22.54B 1.21B Mar/2026
Medtronic USD 6.36B 286M Jun/2026
Merck USD 12.21B 435M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.85B 252M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Novo Nordisk DKK 114.94B 8.68B Jun/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.19B 19M Jun/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 187.36M 4.56M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sanofi EUR 492M 10M Jun/2026
Sanofi EUR 482M 85M Mar/2026
United Therapeutics USD 310.3M 1.7M Jun/2026
Zoetis USD 1.57B 65M Jun/2026